NCCN Oncology Research Program to Evaluate Futibatinib as Monotherapy and in Combo for Malignancies with FGFR 1-4 Aberrations

NCCN Oncology Research Program to Evaluate Futibatinib as Monotherapy and in Combo for Malignancies with FGFR 1-4 Aberrations

The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) announced initiatives for the first time to evaluate a potent and selective inhibitor of the fibroblast growth receptor (FGFR), known as futibatinib (TAS-120). Inclusive of pre-clinical,...

Pin It on Pinterest